SHANDONG XINHUA (00719) announced that the company has recently received the Drug Registration Certificate for Bisoprolol Fumarate Tablets, approved and issued by the National Medical Products Administration. The approval of this product further enriches the company's cardiovascular and cerebrovascular product portfolio, providing additional options for clinical medication.